This is the authors' abstract. We don't add key points for this paper.
Objective: Aim to evaluate the efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in essential tremor (ET). Background: Essential tremor significantly impairs patient autonomy and often responds poorly to standard pharmacological or surgical treatments. rTMS may be an option after first-line therapy failure, though its efficacy remains uncertain, requiring further investigation into its therapeutic potential and safety. Design/Methods: We conducted a systematic review and meta-analysis following PRISMA guidelines, extracting data from PubMed, Embase, and Cochrane databases. We included studies that compared patients with ET treated with rTSM with patients treated with shaw therapy or other therapy available. The primary outcome was the Fahn-Tolosa-Marin (FTM) total score, with secondary outcomes being the FTM subscale A (tremor severity), subscale B (motor task), and subscale C (functional disability). All of the outcomes were analyzed after 1 month of follow-up. Proportions with 95% confidence intervals (CIs) were calculated using a random-effects model. Statistical analysis was performed in RStudio version 4.2.3. Results: Three randomized clinical trials (RCTs) involving ET 89 patients with a mean age of 55.3 years were analyzed. rTMS significantly reduced the total FTM score (MD: −13.39; [−14.67, −12.12]; I 2 = 0%), demonstrating consistent efficacy. Tremor severity improved (MD: −3.03; [−5.56, −0.49]), though heterogeneity was high (I 2 = 87%). rTMS also enhanced motor task performance (MD: −4.70; [−6.58, −2.82]; I 2 = 15%) and reduced functional disability (MD: −2.99; [−3.37, −2.62]; I 2 = 0%), therefore, showing significant benefits across all measures. Conclusions: Our study demonstrates that rTMS significantly improves tremor severity, motor function, and daily activities in essential tremor patients. However, the safety profile of rTMS should be better determined in further studies. RCTs with larger patient populations are needed to optimize treatment protocols. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Mr. Abraham has nothing to disclose. Mr. De Sousa Marinho Mendes Filho has nothing to disclose. Miss Silva has nothing to disclose. Miss Salema Pascual has nothing to disclose. Mr. Fukunaga has nothing to disclose. Miss Weba has nothing to disclose. Mr. NOGUEIRA has nothing to disclose. Miss Nascimento has nothing to disclose. Miss Barbosa has nothing to disclose. Dr. Ogasawara has nothing to disclose. Dr. Pipek has nothing to disclose. Prof. Feitoza has nothing to disclose.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Filho et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: